Abstracts tagged "T-Regulatory Cells and autoimmune diseases"

Abstract Number: 936 • 2018 ACR/ARHP Annual Meeting
Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
Takayuki Katsuyama¹, Hao Li¹, Denis Comte², Michael W. Mosho³, Andrew R. Gillooly³, George C Tsokos⁴ and Vaishali R. Moulton¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Rheumatology, Department of Medicine, Boston, MA, ³Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling and cytokine production, and aberrant numbers and/or function of regulatory T…
Abstract Number: 3109 • 2016 ACR/ARHP Annual Meeting
Regulatory T Cells Deficient in Protein Phosphatase 2A Lose Suppressive Function and Convert to an Effector Phenotype
Isaac R. Kasper¹, Hao Li¹, Sokratis Apostolidis², Maria G. Tsokos³ and George C. Tsokos⁴, ¹Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Medicine/Rheumatology, Harvard Medical School Beth Israel, Boston, MA
Background/Purpose: Regulatory T cells (Tregs) represent the fundamental T-cell capable of promoting self-tolerance and balancing excessive inflammation. Quantitative and qualitative Treg deficiencies have been characterized…
Abstract Number: 2850 • 2014 ACR/ARHP Annual Meeting
MiR-125a Is Critical Regulator for Controlling Autoimmunity in Multiple Autoimmune Diseases through Stabilizing Treg Mediated Immune Homeostasis
Wan Pan^1,2, Shu Zhu², Dai Dai², John Harley³ and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Although different autoimmune diseases show distinct clinical phenotypes, common cellular and molecular immune pathways have been shown to be intimately involved in the autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].